These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

868 related items for PubMed ID: 19460509

  • 1. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M.
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [Abstract] [Full Text] [Related]

  • 2. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 3. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 May; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 4. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G, Tryphonopoulos P, Gaynor JJ, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Powell RH, Ruiz P, Vianna R, Burke GW.
    Transplant Proc; 2016 May; 48(6):2006-10. PubMed ID: 27569936
    [Abstract] [Full Text] [Related]

  • 5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 6. Belatacept for kidney transplant recipients.
    Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.
    Cochrane Database Syst Rev; 2014 Nov 24; 2014(11):CD010699. PubMed ID: 25416857
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

  • 8. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, Moore J, Allwood M, Lowe J, Hyde C, Hoyle M, Bond M, Anderson R.
    Health Technol Assess; 2016 Aug 27; 20(62):1-594. PubMed ID: 27578428
    [Abstract] [Full Text] [Related]

  • 9. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A, Dębska-Ślizień A, Król E, Biedunkiewicz B, Rutkowski B.
    Transplant Proc; 2014 Oct 27; 46(8):2714-8. PubMed ID: 25380901
    [Abstract] [Full Text] [Related]

  • 10. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
    Jiménez-Pérez M, González Grande R, Rando Muñoz FJ, de la Cruz Lombardo J, Muñoz Suárez MA, Fernández Aguilar JL, Pérez Daga JA, Santoyo-Santoyo J, Manteca González R, Rodrigo López JM.
    Transplant Proc; 2015 Oct 27; 47(1):90-2. PubMed ID: 25645779
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 27; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 12. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ, Yang HC, Holman MJ, Ahsan N.
    J Transpl Coord; 1999 Jun 27; 9(2):114-8. PubMed ID: 10703393
    [Abstract] [Full Text] [Related]

  • 13. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?
    Meiser BM, Groetzner J, Kaczmarek I, Landwehr P, Müller M, Jung S, Uberfuhr P, Fraunberger P, Stempfle HU, Weis M, Reichart B.
    Transplantation; 2004 Aug 27; 78(4):591-8. PubMed ID: 15446320
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
    Krämer BK, Neumayer HH, Stahl R, Pietrzyk M, Krüger B, Pfalzer B, Bourbigot B, Campbell S, Whelchel J, Eris J, Vitko S, Budde K, RADA2307 Study Group.
    Transplant Proc; 2005 Apr 27; 37(3):1601-4. PubMed ID: 15866684
    [Abstract] [Full Text] [Related]

  • 16. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK, Klinger M, Vítko Š, Glyda M, Midtvedt K, Stefoni S, Citterio F, Pietruck F, Squifflet JP, Segoloni G, Krüger B, Sperschneider H, Banas B, Bäckman L, Weber M, Carmellini M, Perner F, Claesson K, Marcinkowski W, Ostrowski M, Senatorski G, Nordström J, Salmela K.
    Transplantation; 2012 Sep 15; 94(5):492-8. PubMed ID: 22858806
    [Abstract] [Full Text] [Related]

  • 17. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus.
    Wang SS, Chou NK, Chi NH, Wu IH, Chen YS, Yu HY, Huang SC, Wang CH, Ko WJ, Tsao CI, Sun CD.
    Transplant Proc; 2008 Oct 15; 40(8):2607-8. PubMed ID: 18929814
    [Abstract] [Full Text] [Related]

  • 18. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
    Loriga G, Ciccarese M, Pala PG, Satta RP, Fanelli V, Manca ML, Serra G, Dessole P, Cossu M.
    Transplant Proc; 2010 May 15; 42(4):1297-302. PubMed ID: 20534285
    [Abstract] [Full Text] [Related]

  • 19. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
    Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH, Yu HY, Chen YS, Tsao CI, Ko WJ, Shun CT.
    Transplant Proc; 2010 Apr 15; 42(3):938-9. PubMed ID: 20430209
    [Abstract] [Full Text] [Related]

  • 20. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M, Snowsill T, Jones-Hughes T, Crathorne L, Cooper C, Varley-Campbell J, Mujica-Mota R, Coelho H, Huxley N, Lowe J, Dudley J, Marks S, Hyde C, Bond M, Anderson R.
    Health Technol Assess; 2016 Aug 15; 20(61):1-324. PubMed ID: 27557331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.